Clinical Trials Browser

Phase 3 × Terminated × 90 days × Clear all

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT01366612 2026-03-09

FLUBUTBI

Phase 3 Terminated

53 enrolled 11 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT04777851 2026-03-09

REPLACE

Phase 3 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Phase 3 Terminated

Melanoma

NCT05171049 2026-02-23

ASTER

Phase 3 Terminated

Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT04876651 2026-02-20

The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only

Phase 3 Terminated

Prostatic Neoplasms

NCT05386550 2026-02-19

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Phase 3 Terminated

166 enrolled 15 charts

Head and Neck Neoplasms, Laryngeal Diseases

NCT05223647 2026-01-28

TRIPLEX

Phase 3 Terminated

Neoplasms, Small Cell Lung Carcinoma

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

Multiple Myeloma

NCT03042169 2025-12-23

SURGIGAST

Phase 3 Terminated

Gastrointestinal

Stomach Neoplasms